Practice parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 66, Issue 7, 2006, Pages 968-975

  Suchowersky, O ^a   Reich, S ^b   Perlmutter, J ^c   Zesiewicz, T ^d   Gronseth, G ^e   Weiner, W J ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c Division of General Medical Sciences   (United States)

^d Movement Disorder Center   (United States)

^e UNIVERSITY OF KANSAS   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; APOMORPHINE; CARBIDOPA; CLONIDINE; DOMPERIDONE; DOPAMINE; FLUORODEOXYGLUCOSE F 18; LEVODOPA;

ARTICLE; AUTONOMIC DYSFUNCTION; BRADYKINESIA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG RESPONSE; ECHOGRAPHY; EVIDENCE BASED PRACTICE; FALLING; HUMAN; HYPOTENSION; MEDICAL PRACTICE; MUSCLE RIGIDITY; NAUSEA; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSING HOME; OLFACTORY DISCRIMINATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; TREMOR; VOMITING; DIFFERENTIAL DIAGNOSIS; HEALTH CARE QUALITY; NEUROLOGY; PRACTICE GUIDELINE; PROGNOSIS; STANDARD; UNITED STATES;

DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROLOGY; PARKINSON DISEASE; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 33646082990     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000215437.80053.d0     Document Type: Article

References (47)

1. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004;19:318-323.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
3. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
4. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
5. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
6. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-486.
7. Colosimo C, Albanese A, Hughes AJ, de Bruin VM, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995;52:294-298.
8. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000;57:369-372.
9. Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999;14:947-950.
10. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;68:434-440.
11. Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord 2001;16:197-201.
12. Hughes AJ. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis. Adv Neurol 1999;80:363-368.
13. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:590-594.
14. Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Mov Disord 2002;17:795-798.
15. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000;43:95-101.
16. Strijks E, van't Hof M, Sweep F, Lenders JW, Oyen WJ, Horstink MW. Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with striatonigral degeneration. J Neurol 2002;249:1206-1210.
17. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-946.
18. Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993;43:962-965.
19. Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002;109:805-811.
20. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995;91:247-250.
21. Bordet R, Benhadjali J, Destee A, Hurtevent JF, Bourriez JL, Guieu JD. Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 1996;11:268-272.
22. Eardley I, Quinn NP, Fowler CJ, et al. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol 1989;64:360-362.
23. Giladi N, Simon ES, Korczyn AD, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. Muscle Nerve 2000;23:731-734.
24. Holmberg B, Kallio M, Johnels B, Elam M. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord 2001;16:217-225.
25. Libelius R, Johansson F. Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy. Muscle Nerve 2000;23:1250-1256.
26. Riley DE, Chelimsky TC. Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:56-60.
27. Rascol O, Sabatini U, Simonetta-Moreau M, Montastruc JL, Rascol A, Clanet M. Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991;54:599-602.
28. Stocchi F, Barbato L, Carbone A, et al. Urodynamic study in the differential diagnosis between multiple system atrophy and Parkinson's disease. Adv Neurol 1993;60:434-437.
29. Thaisetthawatkul P, Boeve BF, Benarroch EE, et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology 2004;62:1804-1809.
30. Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994;35:420-426.
31. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-67.
32. Righini A, Antonini A, Ferrarini M, et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. J Comput Assist Tomogr 2002;26:266-271.
33. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
34. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003;60:74-77.
35. Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-523.
36. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-312.
37. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-1228.
38. Messa C, Volonte MA, Fazio F, et al. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 1998;25:1270-1276.
39. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-1032.
40. Antonini A, Kazumata K, Feigin A, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-274.
41. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology 1998;51:1075-1080.
42. Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003;60:529-533.
43. Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol 2003;25:94-109.
44. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
45. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
46. Parashos SA, Maraganore DM, O'Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 2002;77:918-925.
47. Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996;11:236-242.